Yan Lavrovsky, Yan A. Ivanenkov, Konstantin V. Balakin, Darya A. Medvedeva and Alexandre V. Ivachtchenko Pages 1075 - 1087 ( 13 )
There has been considerable in vivo evidence that chemokine receptor CXCR4 and its endogenous ligand CXCL12 modulate some important physiological and pathophysiological processes, including cancer metastasis, angiogenesis, invasion, growth and progression. In this review we elucidate key aspects of CXCL12-CXCR4 signaling system with emphasis on peptide-based and small-molecule CXCR4 inhibitors.
Chemokine, chemokine receptor, CXCR4, CXCL12, SDF-1, tumor, cancer, drugs, inhibitors, antagonists
Small Molecule Drug Discovery, ChemDiv, Inc., San Diego, California, 92121 USA.